A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 133
- Registration Number
- NCT05133882
- Locations
- 🇨🇳
the First Affiliated Hospital,College of Medicine,Zhejiang University, Hanzhou, China
A Clinical Trial of HEC93077 in Chinese Healthy Subjects and HUA Patients With Single or Multiple Dosing
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT05127772
- Locations
- 🇨🇳
Peking Universicity Care of Luzhong Hospital, Zibo, Shandong, China
ADME Study of [14C]- Rongliflozin in Healthy Male Subjects
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05109078
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Phase ll Study of HEC585 in Patients With IPF
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 270
- Registration Number
- NCT05060822
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
ADME Study of [14C]- Larotinib in Healthy Male Subjects
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05059743
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05057949
- Locations
- 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05048368
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chendu, Sichuan, China
Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT04992858
The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT04984512
Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir Study of HEC116094 in Healthy Adult Subjects
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT04982913
- Locations
- 🇨🇳
The Shanghai xuhui district central hospital, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath